Engulfing Line (Bullish)
|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's Range||24.08 - 25.31|
|52 Week Range||12.39 - 30.41|
|Beta (5Y Monthly)||1.87|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 04, 2020 - Aug 10, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||29.73|
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings. The 13F filings show the hedge funds' and successful investors' positions as of the end of the first quarter. You can find articles about an individual hedge fund's trades on numerous financial […]
Denali Therapeutics Inc. (DNLI) announced that it is pausing clinical studies of DNL747, its neurological drug candidate for the treatment of Alzheimer’s disease and ALS, sending shares down some 7% in after-market trading on Tuesday.The stock dropped almost 7% to $23.95 in late market trading after the biotech company said that the decision was made following results from Phase 1b studies of the small molecule RIPK1 inhibitor DNL747 in Alzheimer's disease and amyotrophic lateral sclerosis (ALS).The study was conducted in partnership with Sanofi (SNYNF) to develop small molecule inhibitors of the RIPK1 enzyme, a new class of potential therapeutic agents for a range of neurological and inflammatory diseases, including ALS.The data demonstrated “emerging evidence that higher levels of target inhibition may be required for maximizing efficacy, and challenges to achieving higher doses imposed by molecule-specific toxicity findings with DNL747”.“Together with our partner Sanofi, we have decided to pause clinical studies with DNL747 and focus our efforts on accelerating development of DNL788, which we believe has superior drug properties and a more rapid path toward proof-of-concept clinical studies in patients in multiple neurological indications," said Denali CEO Ryan Watts.RIPK1, receptor-interacting serine/threonine-protein kinase 1, is a critical signaling protein in the TNF receptor pathway, which regulates inflammation and cell death in tissues throughout the body.Denali reported that data from the completed Phase 1 study with peripherally-restricted RIPK1 inhibitor DNL758 in healthy patients display an encouraging profile, as the molecule appears safe and tolerable at doses tested. Denali partner Sanofi is in charge of the development of DNL758 and is currently planning further clinical studies in multiple indications based on successful Phase 1 data.Investors have been enthusiastic about Denali, pushing shares up 56% so far this year to trade at $25.71 as of Tuesday’s close.Earlier this month, five-star analyst Andrew Fein at H.C. Wainwright reiterated a Buy rating on the stock with a $28 price target, saying that Denali’s blood brain pressure barrier (BBB) transport vehicle platform, which leverages receptor-mediated transcytosis (RMT) as a noninvasive strategy for enhancing brain exposure of biotherapeutics, can present a broad future value driver for the company.Denali scores 5 Buys from Wall Street analysts adding up the Strong Buy consensus for the stock. With an average price target of $27.60, analysts still expect shares to add a moderate 7.3% over the coming 12 months. (See Denali stock analysis on TipRanks).Related News: Sorrento’s COVID-19 Cocktail Could Drive Major Upside, Says Analyst Oxford Biomedica Clinches Manufacturing Deal For AstraZeneca’s Covid-19 Vaccine Global Blood Therapeutics Up On Expanded Use Plans For Sickle Cell Treatment More recent articles from Smarter Analyst: * Aurora Cannabis Leap Frogs Canopy Growth as a Better Investment * Afrezza Could Push MannKind Shares Higher, Says 5-Star Analyst * Shopify Teams Up With Blackberry On Canadian Covid-19 App * Marathon- Speedway Sale Reportedly Back In Play; RBC Says Deal ‘Clear Positive’
Denali and Sanofi pause DNL747(a) clinical activities based on the totality of DNL747 data and a superior profile of backup compound DNL788(b)Denali and Sanofi intend to.
Flagship Pioneering, a unique life sciences innovation enterprise, today announced that it has further strengthened its executive leadership team with the appointment of Fabrice Chouraqui to the newly created dual role as both CEO-Partner of Flagship Pioneering and Chief Executive Officer of Cellarity.
Denali’s “Transport Vehicle” technology enables broad distribution and improved exposure levels of therapeutic proteins throughout the brainClinical proof of concept data with.
Denali Therapeutics Inc. (DNLI) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank 2 (Buy).
Investors in Denali Therapeutics Inc. (NASDAQ:DNLI) had a good week, as its shares rose 9.6% to close at US$23.89...
Denali Therapeutics Inc (DNLI) delivered earnings and revenue surprises of 3.51% and -39.19%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
SOUTH SAN FRANCISCO, May 07, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross.
Denali Therapeutics Inc. (DNLI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]
In the span of eight days last month, CytomX Therapeutics Inc. landed a collaboration with Astellas Pharma and captured a $40 million milestone payment from AbbVie Inc. as it preps for a mid-stage cancer clinical trial. “It’s a challenging time for our industry,” said CytomX President and CEO Sean McCarthy.
“In these unprecedented times, our resolve to defeat degeneration is undiminished and our top priority is to ensure the health and safety of our employees, community, partners and clinical trial participants,” said Ryan Watts, Ph.D., CEO. For the ongoing DNL151 Phase 1 and Phase 1b trials, enrollment of additional healthy volunteers and patients at higher doses has been paused due to the COVID-19 pandemic. Denali is analyzing available data from these trials and is on track to select either DNL201 or DNL151 by mid-2020 to progress into Phase 2/3 trials.
It's been a mediocre week for Denali Therapeutics Inc. (NASDAQ:DNLI) shareholders, with the stock dropping 19% to...
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered.
If you want a stock market bet that’s 74% likely to lose money, try investing in high-flying stock that sells for 100 times revenue or more Continue reading...
Chief Medical Officer and Head of Development Company: Denali Therapeutics HQ: South San Francisco Years at company: 5 Career turning point: Switching from clinical medicine to research and moving into a management role at Genentech Advice: Women need to be very intentional with networking, Ho says. “I always encourage people to not apologize for the things they do outside of work, be proud of them, talk about them at work and incorporate them into your work life balance.” Carole Ho’s wending career path to biotech startup Denali Therapeutics brought big risks — and big rewards. In 2002, she had just finished her residency in neurology at Massachusetts General Hospital and Brigham and Women’s Hospital for Harvard Medical School when she decided to chance it all and move west to work in a lab at Stanford University.
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2020 -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced the closing of its upsized underwritten public offering of 9,000,000.
Vertex (VRTX) rides high on earnings and revenue beat in Q4. The company provides solid outlook for 2020 resulting in the shares to go up in after-hours trading.
Denali Therapeutics Inc. (DNLI) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
Intercept (ICPT) closes enrollment in late-stage study evaluating obeticholic acid for the treatment of compensated cirrhosis due to nonalcoholic steatohepatitis.